Navigation Links
CLRS Technology Accelerates Infrastructure Growth Anticipating FDA Clearance for At-Home IPL Acne Device
Date:5/28/2008

CLARO To Enter $255 Million Home-Device Market With First-to-Market

Technology, Strong Branding

COSTA MESA, Calif., May 28 /PRNewswire/ -- CLRS Technology today announced a series of corporate milestones in anticipation of FDA clearance for CLARO, the company's innovative at-home acne treatment device. Key business developments include the appointment of a senior marketing executive, expansion of the Board of Directors, commencement of clinical studies and receipt of a design patent.

"It's an incredibly exciting time at CLRS Technology as we put all the pieces in place to succeed in bringing our flagship product launch to life," said Richard Oberreiter, CEO and Founder, CLRS Technology. "As we await FDA clearance for CLARO, we are energized by the level of interest and support from the financial and medical community. We have the right team in place to make CLARO a success within one of the fastest growing categories of the aesthetic industry."

CLRS Technology is poised to enter the $255 million home device category with CLARO, a hand-held Intense Pulse Light (IPL) system based on the same technology used by dermatologists for decades. This flagship product will be the first in a series of hand-held tools designed to provide professional-based solutions for common skin and allergy conditions. According to Medical Insight Inc, the category is expected to grow to $1 billion in retail sales by 2012 with major corporations setting the pace, including Palomar with Gillette, Syneron and Procter & Gamble, and Light BioScience with L'Oreal.

"We see tremendous opportunity entering this market with a unique acne treatment device that fulfills a consumer need for science-based technology that's safe, convenient and effective," said Mr. James Kraushaar, Chairman & Founder, CLRS Technology, whose extensive 15+ years of experience marketing and selling medical IPL systems and aesthetic lasers fueled the development of CLARO. "Chronic acne can damage self-esteem in teens and adults, and current solutions fall short in providing immediate relief. We believe CLARO will improve the quality of life for sufferers of mild to moderate acne."

According to Mr. Oberreiter, FDA-clearance for CLARO is anticipated this summer and prescription sales are expected to start in August at dermatologists and family practitioners.

Executive Appointment

Beauty industry entrepreneur James Pereyra joined CLRS Technology this month as Chief Marketing Officer to oversee branding, advertising and marketing campaigns. Mr. Pereyra was CEO and Founder of fenix Cosmetics Inc., a manufacturer of one of the nation's top professional skincare brands retailing at dermatologists, plastic surgeons, medical spas and fenix stores throughout the US, Asia and Middle East.

Product Milestones

This month also marked the beginning of clinical study for the CLARO under the leadership of Dr. Ronald Moy, Former Co-Chief of the Department of Dermatology and Chief of Dermatologic Surgery, UCLA. The study is designed to evaluate CLARO's efficacy in resolving acne lesions at 24, 48 and 120 hours.

"I am impressed with the science behind CLARO and anticipate it will perform well in our clinical study," said Dr. Moy. "Acne is one of the most difficult chronic conditions to treat and I believe that CLARO will offer a valuable at-home solution for teenagers and adults of all ages who want fast results in treating their acne. CLARO will also enable me to provide better outcomes for my patients by supplementing the care I can provide in-office."

Also this month, CLRS Technology was awarded a design patent for CLARO, a welcome advantage in the highly competitive marketplace. The patent covers unique components of the CLARO's industrial design and ergonomic features. CLRS Technology also has multiple pending patents relating to its technology platform that is capable of delivering dermatologist quality results in a home environment.

Board of Directors

Mr. Oberreiter announced the appointment of Jeffrey Jones, CEO of Technology4Medicine, LLC to the CLRS Technology Board of Directors. Mr. Jones is a well-regarded veteran of the medical and dental laser industry having served as CEO of Biolase (Nasdaq: BLTI) and HGM Medical Lasers Systems. While at Biolase, Mr. Jones was responsible for growing the company to $70 million in revenues and a 70 to 80 percent market share in dental lasers.

About CLRS Technology

Established in 2007, CLRS Technology is a manufacturing company that specializes in development of innovative and clinically-proven consumer hand-held medical devices that deliver at-home solutions for common skin and allergy problems that were previously only available at a medical or aesthetic professional's office.


'/>"/>
SOURCE CLRS Technology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology
2. Life-Saving Technology Expands Globally to Military Branches - Transforming the Way Medical Care is Documented on the Battlefield
3. Utah Schools Leading the Nation in Adopting Technology to Manage Individual Student Achievement
4. Pioneer(R) Surgical Technology Introduces the BacJac(TM) Interspinous Decompression System to the European Spine Market
5. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
6. Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008
7. MediVoice Announces Appointment of Edward J. Zecchini as Chief Operating Officer & Chief Technology Officer
8. Align Technology Names Dana C. Cambra as VP, Research & Development
9. RTX Healthcare Launch Wireless Telehealth Monitor With Built-in GSM/GPRS Mobile Phone Technology
10. New Surgical Technology Holds Promise of Painless, Scarless Procedures
11. New Technology Speeds GI Disease Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , ... March 30, 2017 , ... According to the ... performed each year, putting it among the top 5 most popular minimally-invasive cosmetic procedures ... those million-plus procedures will be performed over the next 8-10 weeks. For anyone considering ...
(Date:3/30/2017)... ... March 30, 2017 , ... Nutrition Education for ... Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating Heart ... to help nutrition educators and students inform consumers about the health benefits of ...
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ... co-op eligible dealer websites for its network of more than 650 U.S.-based dealers. Rhino, ... agricultural equipment including rotary and flail mowers and cutters, rear blades, post hole diggers, ...
(Date:3/29/2017)... ... ... Grass pollen is the main cause of hay fever in the United States, with an ... runs from May to July each year; with the worst time for sufferers being June ... balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in ...
(Date:3/29/2017)... ... ... Sports Brand EXOUS Bodygear announced today a special sale price for the ... days of March, the price will be only $19.97. The EXOUS Bodygear 65cm ... (regular retail price $19.97). , The special promotional prices are to help individuals get ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... Proton Therapy Market in Italy will double ... are currently three proton therapy centers in Italy ... Italy , the first patients were treated with proton beams ...
(Date:3/29/2017)... 2017  Providence Medical Technology, Inc., an innovator ... two industry veterans to the commercial leadership team.  ... to lead Global Marketing, and Michael Scott ... and Mr. Scott have over 40 years of ... joins the company with over 22 years of ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
Breaking Medicine Technology: